Sana Biotechnology Reports Third Quarter 2026 Financial Results and Business Updates
Globe Newswire•05/11/2026•16:05 ET
0
Key Highlights
- ➤Cash position $121.7 million; runway expected into mid-2027
- ➤Net income $20.4 million, or $0.07 per share, in Q3 2026
- ➤SC451 Phase 1/2 trial expected to begin as early as this year
- ➤SG293 clinical study in non-Hodgkin lymphoma expected in 1Q 2027
- ➤UP421 14-month data showed sustained beta-cell function without immunosuppression
Expert Statements
Steve Harr, President and Chief Executive Officer of Sana Biotechnology
“We continue to make meaningful progress toward initiating clinical studies of SC451 later this year and SG293 in 1Q 2027,”
Steve Harr, President and Chief Executive Officer of Sana Biotechnology
“We aim to share data from both of these programs in 2027 and anticipate both have the potential for relatively rapid proof of concept.”
Steve Harr, President and Chief Executive Officer of Sana Biotechnology
“In particular, SC451 in type 1 diabetes may provide a rapid signal, similar to what was seen with UP421, on whether the therapy can evade immune detection and function in patients.”
Continued progress toward starting SC451 Phase 1/2 trial in type 1 diabetes
Continued progress toward starting clinical study for SG293 in non-Hodgkin lymphoma
Get started
Create a free account to read the full story.